➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Dow
Medtronic
Merck
Express Scripts

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020702


Email this page to a colleague

« Back to Dashboard

NDA 020702 describes LIPITOR, which is a drug marketed by Upjohn and is included in one NDA. It is available from six suppliers. Additional details are available on the LIPITOR profile page.

The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.
Summary for 020702
Tradename:LIPITOR
Applicant:Upjohn
Ingredient:atorvastatin calcium
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020702
Medical Subject Heading (MeSH) Categories for 020702
Suppliers and Packaging for NDA: 020702
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LIPITOR atorvastatin calcium TABLET;ORAL 020702 NDA Parke-Davis Div of Pfizer Inc 0071-0155 0071-0155-10 1000 TABLET, FILM COATED in 1 BOTTLE (0071-0155-10)
LIPITOR atorvastatin calcium TABLET;ORAL 020702 NDA Parke-Davis Div of Pfizer Inc 0071-0155 0071-0155-23 90 TABLET, FILM COATED in 1 BOTTLE (0071-0155-23)
Paragraph IV (Patent) Challenges for 020702
Tradename Dosage Ingredient NDA Submissiondate
LIPITOR TABLET;ORAL atorvastatin calcium 020702

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Dec 17, 1996TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 20MG BASE
Approval Date:Dec 17, 1996TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 40MG BASE
Approval Date:Dec 17, 1996TE:ABRLD:Yes

Expired US Patents for NDA 020702

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Moodys
Baxter
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.